LC
TEVA icon

Lindbrook Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Lindbrook Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$15.1K Sell
981
-323
-25% -$5.77K ﹤0.01% 1479
2024
Q4 		$28.7K Buy
1,304
+32
+3% +$582 ﹤0.01% 1085
2024
Q3 		$22.9K Sell
1,272
-28
-2% -$490 ﹤0.01% 1219
2024
Q2 		$21.1K Buy
1,300
+319
+33% +$4.91K ﹤0.01% 1220
2024
Q1 		$13.8K Hold
981
– – ﹤0.01% 1392
2023
Q4 		$10.2K Buy
981
+352
+56% +$3.29K ﹤0.01% 1538
2023
Q3 		$6.42K Hold
629
– – ﹤0.01% 1650
2023
Q2 		$4.74K Sell
629
-157
-20% -$1.27K ﹤0.01% 1832
2023
Q1 		$6.96K Hold
786
– – ﹤0.01% 1690
2022
Q4 		$7.17K Sell
786
-66
-8% -$576 ﹤0.01% 1605
2022
Q3 		$7K Buy
852
+30
+4% +$265 ﹤0.01% 1515
2022
Q2 		$6K Sell
822
-93
-10% -$810 ﹤0.01% 1497
2022
Q1 		$9K Sell
915
-367
-29% -$3.06K ﹤0.01% 1343
2021
Q4 		$10K Buy
1,282
+801
+167% +$7.23K ﹤0.01% 1284
2021
Q3 		$5K Hold
481
– – ﹤0.01% 1263
2021
Q2 		$5K Hold
481
– – ﹤0.01% 1309
2021
Q1 		$6K Hold
481
– – ﹤0.01% 1227
2020
Q4 		$5K Sell
481
-684
-59% -$6.55K ﹤0.01% 1209
2020
Q3 		$10K Sell
1,165
-976
-46% -$10.3K ﹤0.01% 844
2020
Q2 		$26K Buy
2,141
+1,620
+311% +$18.3K 0.01% 535
2020
Q1 		$5K Sell
521
-1,222
-70% -$12.5K ﹤0.01% 1023
2019
Q4 		$17K Sell
1,743
-2,718
-61% -$24.3K 0.01% 785
2019
Q3 		$31K Buy
4,461
+1,935
+77% +$14.8K 0.01% 563
2019
Q2 		$23K Buy
2,526
+37
+1% +$446 0.01% 649
2019
Q1 		$39K Buy
2,489
+945
+61% +$16.7K 0.02% 492
2018
Q4 		$23K Buy
+1,544
New +$31.7K 0.01% 567

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Lindbrook Capital's TEVA Position: Q1 2025 in Review

Lindbrook Capital reduced its Teva Pharmaceuticals (TEVA) stake by 25% in Q1 2025, selling an estimated $5.77K and leaving 981 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1479.

Lindbrook Capital first reported a position in TEVA in Q4 2018 and has held it in 26 quarters since. The position peaked at $39K in Q1 2019. 561 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Lindbrook Capital held 981 shares of Teva Pharmaceuticals worth $15.1K as of Q1 2025.
  • Lindbrook Capital sold 323 Teva Pharmaceuticals shares in Q1 2025, an estimated $5.77K.
  • Teva Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1479 holding.
  • Lindbrook Capital first reported a position in Teva Pharmaceuticals in Q4 2018 and has held it in 26 quarters since.
  • Lindbrook Capital's Teva Pharmaceuticals position peaked at $39K in Q1 2019.
  • 561 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.